Index -
P/E -
EPS (ttm) -19.78
Insider Own 0.69%
Shs Outstand 1.24M
Perf Week 9.09%
Market Cap 16.38M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 1.23M
Perf Month -2.86%
Income -15.95M
PEG -
EPS next Q -
Inst Own 12.69%
Short Float 0.77%
Perf Quarter -13.60%
Sales 111.12M
P/S 0.15
EPS this Y -
Inst Trans -55.85%
Short Ratio 2.47
Perf Half Y -15.42%
Book/sh 61.13
P/B 0.22
EPS next Y -
ROA -4.20%
Short Interest 0.01M
Perf Year 15.89%
Cash/sh 26.88
P/C 0.49
EPS next 5Y 46.00%
ROE -23.68%
52W Range 8.98 - 24.20
Perf YTD -12.45%
Dividend Est. -
P/FCF -
EPS past 5Y 35.15%
ROI -6.55%
52W High -45.40%
Beta 1.41
Dividend TTM -
Quick Ratio 1.21
Sales past 5Y -25.86%
Gross Margin 59.49%
52W Low 47.15%
ATR (14) 0.83
Dividend Ex-Date -
Current Ratio 1.59
EPS Y/Y TTM 90.77%
Oper. Margin -29.68%
RSI (14) 50.87
Volatility 4.97% 6.03%
Employees 122
Debt/Eq 3.16
Sales Y/Y TTM -10.43%
Profit Margin -14.35%
Recom 1.00
Target Price 200.00
Option/Short No / Yes
LT Debt/Eq 3.13
EPS Q/Q 37.27%
Payout -
Rel Volume 1.20
Prev Close 11.91
Sales Surprise -
EPS Surprise -
Sales Q/Q -17.30%
Earnings Apr 01 AMC
Avg Volume 3.84K
Price 13.21
SMA20 3.32%
SMA50 -8.43%
SMA200 -2.05%
Trades
Volume 4,617
Change 10.92%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-17-21 Upgrade
H.C. Wainwright
Neutral → Buy
$5 → $10
Aug-14-19 Downgrade
H.C. Wainwright
Buy → Neutral
$31 → $6
May-23-19 Initiated
Wedbush
Neutral
Dec-11-18 Downgrade
Goldman
Neutral → Sell
Aug-07-18 Reiterated
Stifel
Hold
$15 → $25
Feb-16-18 Upgrade
Piper Jaffray
Neutral → Overweight
Jan-17-18 Reiterated
H.C. Wainwright
Buy
$34 → $31
Nov-28-17 Resumed
Piper Jaffray
Neutral
$22
Nov-16-17 Downgrade
Stifel
Buy → Hold
$26 → $15
Nov-16-17 Downgrade
Raymond James
Mkt Perform → Underperform
Nov-09-17 Initiated
Oppenheimer
Perform
Nov-08-17 Initiated
H.C. Wainwright
Buy
$35
Oct-06-17 Resumed
Goldman
Sell
$20
Jul-11-17 Initiated
Jefferies
Hold
Apr-03-17 Downgrade
JP Morgan
Overweight → Neutral
Feb-15-17 Upgrade
Goldman
Sell → Neutral
Nov-30-16 Upgrade
JP Morgan
Neutral → Overweight
Oct-04-16 Resumed
Leerink Partners
Mkt Perform
$25
Mar-30-16 Initiated
Goldman
Sell
Sep-01-15 Initiated
Raymond James
Mkt Perform
Show Previous Ratings
Mar-25-24 04:01PM
Jan-11-24 08:01AM
Nov-14-23 10:34AM
Nov-13-23 04:07PM
(Associated Press Finance)
04:01PM
04:01PM
Loading…
Nov-06-23 04:01PM
08:00AM
Aug-28-23 12:42PM
Aug-08-23 04:21PM
(Associated Press Finance) -6.25%
04:01PM
Aug-02-23 08:00AM
Aug-01-23 08:00AM
Jun-28-23 05:08PM
Jun-26-23 08:23AM
Jun-05-23 09:06AM
04:01PM
Loading…
Jun-02-23 04:01PM
May-31-23 04:01PM
May-30-23 08:00AM
May-12-23 05:28AM
(Thomson Reuters StreetEvents) -17.25%
May-11-23 04:29PM
04:01PM
02:26PM
May-10-23 07:00AM
May-08-23 07:00AM
May-04-23 09:41AM
Apr-24-23 08:00AM
Apr-03-23 08:00AM
Mar-27-23 08:00AM
Mar-09-23 07:00AM
Mar-07-23 07:00AM
03:43PM
Loading…
Mar-06-23 03:43PM
Feb-14-23 04:46PM
Jan-31-23 04:01PM
Jan-05-23 04:20PM
Dec-22-22 08:00AM
Dec-20-22 05:30PM
Dec-05-22 07:01AM
Nov-19-22 08:12AM
Nov-11-22 09:52AM
Nov-04-22 09:25AM
Nov-01-22 04:01PM
Oct-27-22 07:00AM
Oct-25-22 04:01PM
Oct-21-22 07:00AM
Oct-19-22 07:00AM
Oct-18-22 07:00AM
Oct-16-22 04:48PM
Oct-10-22 06:30AM
Sep-08-22 04:01PM
Aug-29-22 07:00AM
Aug-19-22 08:00AM
Aug-04-22 04:01PM
Jul-28-22 04:01PM
Jun-16-22 09:31AM
07:01AM
May-11-22 04:01PM
04:01PM
May-04-22 04:01PM
Mar-09-22 04:01PM
Feb-24-22 05:00PM
Jan-04-22 07:11AM
Jan-03-22 04:01PM
Nov-09-21 04:01PM
04:01PM
Nov-02-21 07:00AM
Sep-09-21 08:01AM
Aug-05-21 05:45PM
04:01PM
Jul-30-21 04:01PM
Jul-27-21 03:02PM
Jul-23-21 07:28AM
Jul-22-21 04:01PM
Jun-18-21 10:46PM
Jun-16-21 07:00AM
May-06-21 05:15PM
04:00PM
Apr-29-21 04:30PM
Apr-27-21 12:00PM
Apr-20-21 09:46AM
Apr-12-21 07:00AM
Apr-01-21 07:51AM
Mar-12-21 10:01AM
Mar-11-21 08:52AM
Mar-10-21 11:30AM
Mar-08-21 11:12PM
05:44PM
Mar-05-21 08:15AM
Mar-04-21 05:45PM
04:01PM
Mar-03-21 12:52PM
Mar-02-21 08:43AM
Feb-26-21 10:10AM
Feb-25-21 07:00AM
Feb-19-21 07:00AM
Feb-11-21 11:12AM
09:13AM
07:00AM
Feb-10-21 10:21AM
Feb-08-21 12:40PM
Feb-04-21 11:48AM
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine), and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa, and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in New York, NY.
Index -
P/E 52.46
EPS (ttm) 0.48
Insider Own 8.31%
Shs Outstand 241.53M
Perf Week 1.46%
Market Cap 6.04B
Forward P/E 15.93
EPS next Y 1.57
Insider Trans -0.69%
Shs Float 221.87M
Perf Month 6.98%
Income 118.10M
PEG 5.30
EPS next Q 0.32
Inst Own 92.72%
Short Float 1.71%
Perf Quarter 6.25%
Sales 2.33B
P/S 2.59
EPS this Y 7.00%
Inst Trans -5.66%
Short Ratio 2.91
Perf Half Y 29.77%
Book/sh 9.64
P/B 2.59
EPS next Y 13.62%
ROA 2.35%
Short Interest 3.80M
Perf Year 33.87%
Cash/sh 1.20
P/C 20.89
EPS next 5Y 9.90%
ROE 4.98%
52W Range 17.08 - 25.05
Perf YTD 7.95%
Dividend Est. 0.27 (1.06%)
P/FCF 21.35
EPS past 5Y -
ROI 2.73%
52W High -0.28%
Beta 1.32
Dividend TTM 0.32 (1.28%)
Quick Ratio 2.43
Sales past 5Y 4.36%
Gross Margin 39.37%
52W Low 46.25%
ATR (14) 0.42
Dividend Ex-Date Feb 29, 2024
Current Ratio 3.24
EPS Y/Y TTM -35.67%
Oper. Margin 11.72%
RSI (14) 68.32
Volatility 1.22% 1.57%
Employees 5300
Debt/Eq 0.87
Sales Y/Y TTM -8.48%
Profit Margin 5.06%
Recom 1.60
Target Price 26.89
Option/Short Yes / Yes
LT Debt/Eq 0.86
EPS Q/Q 606.65%
Payout 65.52%
Rel Volume 0.88
Prev Close 24.89
Sales Surprise -2.88%
EPS Surprise -2.05%
Sales Q/Q -0.07%
Earnings Feb 20 AMC
Avg Volume 1.30M
Price 24.98
SMA20 3.49%
SMA50 6.88%
SMA200 19.55%
Trades
Volume 1,144,043
Change 0.36%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-01-24 Initiated
Wolfe Research
Peer Perform
Jun-20-23 Initiated
BMO Capital Markets
Outperform
$23
Oct-13-22 Initiated
Goldman
Neutral
$20
Oct-06-22 Initiated
Credit Suisse
Underperform
$15
Jul-11-22 Upgrade
Barclays
Equal Weight → Overweight
$24 → $22
Jan-24-22 Initiated
CL King
Buy
$28
Oct-13-21 Initiated
Mizuho
Buy
$27
Jun-10-21 Initiated
Wolfe Research
Outperform
Oct-13-20 Initiated
Loop Capital
Buy
$19
Apr-20-20 Upgrade
SunTrust
Hold → Buy
$11
Nov-18-19 Upgrade
Goldman
Neutral → Buy
Feb-11-19 Resumed
Barclays
Equal Weight
$13
Show Previous Ratings
Mar-21-24 11:30AM
Mar-19-24 08:57AM
Feb-22-24 08:40AM
Feb-21-24 10:23PM
(Thomson Reuters StreetEvents)
07:20AM
05:45PM
Loading…
Feb-20-24 05:45PM
04:55PM
(Associated Press Finance)
04:54PM
04:15PM
Feb-16-24 01:01PM
Feb-15-24 04:30PM
Feb-13-24 04:15PM
10:00AM
08:35AM
Jan-30-24 04:30PM
12:41PM
Loading…
Jan-05-24 12:41PM
Jan-04-24 08:00AM
Dec-20-23 06:37AM
Dec-18-23 04:15PM
Dec-12-23 08:48AM
Dec-07-23 07:30AM
Nov-29-23 08:00AM
Nov-24-23 11:31AM
Nov-20-23 08:42AM
Nov-16-23 04:15PM
Nov-07-23 08:00AM
Nov-04-23 12:18PM
Oct-30-23 01:38AM
Oct-28-23 11:27AM
Oct-27-23 10:44AM
10:07PM
Loading…
Oct-26-23 10:07PM
(Thomson Reuters StreetEvents)
Oct-25-23 08:00PM
06:50PM
06:18PM
05:51PM
(Associated Press Finance)
04:15PM
Oct-20-23 04:32AM
Oct-19-23 08:15AM
Oct-18-23 10:01AM
Oct-11-23 04:30PM
11:40AM
07:00AM
Oct-04-23 08:00AM
Sep-14-23 11:26AM
Sep-12-23 09:00AM
Sep-06-23 07:30AM
Aug-25-23 11:31AM
Aug-22-23 04:15PM
Jul-27-23 09:54AM
Jul-26-23 07:05PM
05:53PM
04:15PM
Jul-20-23 10:02AM
Jul-19-23 10:01AM
Jul-12-23 04:30PM
Jul-05-23 09:40AM
Jul-01-23 10:12AM
Jun-29-23 09:13AM
Jun-20-23 09:33AM
Jun-19-23 11:40AM
09:40AM
Jun-12-23 07:20AM
Jun-08-23 11:30AM
Jun-05-23 07:30AM
Jun-02-23 11:31AM
May-26-23 11:31AM
06:06AM
May-22-23 04:30PM
May-14-23 09:08AM
Apr-27-23 10:26PM
(Thomson Reuters StreetEvents)
08:49AM
08:32AM
Apr-26-23 06:25PM
04:15PM
Apr-20-23 10:02AM
Apr-19-23 10:01AM
Apr-12-23 04:30PM
Apr-06-23 08:38AM
Mar-23-23 07:59AM
Mar-09-23 06:47AM
Mar-08-23 04:30PM
Feb-24-23 07:17AM
Feb-23-23 05:58AM
Feb-22-23 04:30PM
Feb-21-23 07:05PM
04:15PM
Feb-17-23 05:28AM
Feb-13-23 04:15PM
Feb-06-23 04:30PM
Jan-22-23 08:23AM
Jan-15-23 09:34AM
Dec-05-22 05:43AM
Nov-25-22 11:31AM
Nov-21-22 05:12AM
Nov-18-22 05:40AM
Nov-17-22 04:15PM
Nov-08-22 05:19AM
Nov-01-22 07:30AM
Oct-27-22 06:18AM
Oct-26-22 05:45PM
Element Solutions, Inc. is a specialty chemicals company. It operates under the Electronics, and Industrial and Specialty segments. The Electronics segment focuses on researching, formulating, and selling specialty chemicals and material process technologies for all types of electronics hardware, from complex printed circuit board designs to advanced semiconductor packaging. The Industrial and Specialty segment includes technologies that enhance surfaces or improve industrial processes in diverse industrial sectors from automotive trim to transcontinental infrastructure and from high-speed printing to high-design faucets. The company was founded by Martin Ellis Franklin on April 23, 2013 and is headquartered in Fort Lauderdale, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fricke Richard L. SVP, Electronics Feb 28 '24 Sale 23.40 9,500 222,300 36,229 Mar 01 04:18 PM Gliklich Benjamin President and CEO Feb 15 '24 Sale 23.20 6,579 152,633 726,399 Feb 15 05:36 PM D'Ambrisi Joseph J. EVP Head of Electronics Feb 15 '24 Sale 23.20 1,771 41,087 410,077 Feb 15 05:40 PM Dorman Carey J. EVP, CFO Feb 15 '24 Sale 23.20 1,410 32,712 177,113 Feb 15 05:39 PM Goralski Michael Former EVP, Head of I&S Feb 15 '24 Sale 23.20 1,169 27,121 146,297 Feb 15 05:41 PM Capps John Edward EVP, General Counsel & Sec. Feb 15 '24 Sale 23.20 1,128 26,170 549,138 Feb 15 05:37 PM Gliklich Benjamin President and CEO Feb 13 '24 Sale 23.20 61,667 1,430,674 704,395 Feb 15 05:36 PM D'Ambrisi Joseph J. EVP Head of Electronics Feb 13 '24 Sale 23.20 14,847 344,450 406,528 Feb 15 05:40 PM Dorman Carey J. EVP, CFO Feb 13 '24 Sale 23.20 14,774 342,757 171,551 Feb 15 05:39 PM Capps John Edward EVP, General Counsel & Sec. Feb 13 '24 Sale 23.20 14,426 334,683 545,366 Feb 15 05:37 PM Goralski Michael Former EVP, Head of I&S Feb 13 '24 Sale 23.20 11,604 269,213 143,446 Feb 15 05:41 PM Maynard-Elliott Nichelle Director Sep 19 '23 Sale 19.61 4,174 81,852 24,789 Sep 19 04:33 PM Goralski Michael EVP, Head of I&S Jun 07 '23 Sale 19.07 28,000 533,960 131,808 Jun 07 04:26 PM Gliklich Benjamin President and CEO Jun 01 '23 Sale 18.01 8,469 152,527 621,208 Jun 01 04:43 PM Dorman Carey J. EVP, CFO Jun 01 '23 Sale 18.00 3,656 65,808 153,222 Jun 01 04:43 PM Gliklich Benjamin President and CEO May 31 '23 Sale 18.03 25,238 455,041 629,677 Jun 01 04:43 PM Dorman Carey J. EVP, CFO May 31 '23 Sale 18.02 2,400 43,248 156,878 Jun 01 04:43 PM Gliklich Benjamin President and CEO May 30 '23 Sale 18.49 166,293 3,074,758 654,915 Jun 01 04:43 PM Dorman Carey J. EVP, CFO May 30 '23 Sale 18.50 23,944 442,964 159,278 Jun 01 04:43 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite